Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Investing Activities (2016 - 2025)

KalVista Pharmaceuticals' Cash from Investing Activities history spans 10 years, with the latest figure at -$3.3 million for Q2 2025.

  • For Q2 2025, Cash from Investing Activities rose 97.36% year-over-year to -$3.3 million; the TTM value through Apr 2025 reached -$43.7 million, up 48.44%, while the annual FY2025 figure was $91.0 million, 207.44% up from the prior year.
  • Cash from Investing Activities for Q2 2025 was -$3.3 million at KalVista Pharmaceuticals, down from $48.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $48.7 million in Q4 2024 and bottomed at -$126.2 million in Q2 2024.
  • The 3-year median for Cash from Investing Activities is $19.6 million (2023), against an average of -$316000.0.
  • The largest annual shift saw Cash from Investing Activities soared 70.45% in 2024 before it surged 97.36% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at $28.6 million in 2023, then skyrocketed by 70.45% to $48.7 million in 2024, then crashed by 106.84% to -$3.3 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Cash from Investing Activities are -$3.3 million (Q2 2025), $48.7 million (Q4 2024), and $37.2 million (Q3 2024).